Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share (the "Shares")
-
Shares outstanding
-
94,401,153
-
Total 13F shares
-
84,525,573
-
Share change
-
+396,463
-
Total reported value
-
$4,321,960,073
-
Put/Call ratio
-
190%
-
Price per share
-
$51.10
-
Number of holders
-
233
-
Value change
-
+$33,724,194
-
Number of buys
-
120
-
Number of sells
-
101
Institutional Holders of Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) as of Q3 2024
As of 30 Sep 2024,
Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) was held by
233 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
84,525,573 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, Driehaus Capital Management LLC, PRICE T ROWE ASSOCIATES INC /MD/, WELLINGTON MANAGEMENT GROUP LLP, FMR LLC, EcoR1 Capital, LLC, STATE STREET CORP, JENNISON ASSOCIATES LLC, and Paradigm Biocapital Advisors LP.
This page lists
233
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.